Inhibikase Therapeutics Inc. (IKT)
IKT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/0000950170-25-046096-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | IKT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001750149 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$27.5M |
| Operating income | -$28.6M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $97.5M |
| Total assets | $98.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $51.7M cash; operating cash flow -$12.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 140,269,633 (2026-11-02); 75,175,306 a year earlier; 6,174,280 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2025-12-19 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CohnReznick LLP, Holmdel, New Jersey, United States; changed auditors 1 time in 24 months | 8-K 4.01 2026-08-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $3.0M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$20.5M | -$17.4M | $51.7M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $0 | -$19.6M | -$12.4M | $31.2M | No debt tags | Needs four quarters | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $0 | -$16.4M | -$12.1M | $49.6M | No debt tags | Needs four quarters | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | Not filed | -$12.7M | -$7.5M | $178.8M | $0 | Needs four quarters | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | $0 | -$11.9M | -$10.6M | $38.3M | $0 | $0 | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $0 | -$9.9M | -$5.6M | $77.7M | $38K | $0 | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $0 | -$13.7M | -$4.1M | $73.4M | $75K | $0 | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $0 | -$12.1M | -$5.3M | $97.5M | $111K | $0 | 10-K 2025-03-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-19 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 370 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.3% |
| 1 month | -13.6% |
| 3 months | -36.9% |
| Year to date | -25.9% |
| 1 year | -5.0% |
| From 52-week high | -39.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LCTX | Lineage Cell Therapeutics Inc. | $0.7951 | -13.07% | $201.1M |
| ARTV | Artiva Biotherapeutics Inc. | $3.96 | -1.25% | $195.8M |
| CGEN | Compugen Ltd. | $2.04 | -2.86% | $193.0M |
| PALI | Palisade Bio Inc. | $1.03 | -8.04% | $184.7M |
| CABA | Cabaletta Bio Inc. | $1.11 | -13.28% | $239.4M |
| PLX | Protalix BioTherapeutics Inc. (DE) | $3.03 | -0.66% | $255.5M |
| IVVD | Invivyd Inc. | $0.5377 | -7.63% | $158.5M |
| OCGN | Ocugen Inc. | $0.7730 | -6.62% | $262.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier